AMSTERDAM--(BUSINESS WIRE)--Jan 13, 2025--
Avanzanite Bioscience B.V., a leading commercial-stage specialty pharmaceutical company committed to bringing ground-breaking medicines for rare diseases to market, announced today the appointment of Jason Cameron as Chief Technical Officer (CTO). This move marks a significant step in Avanzanite’s mission to accelerate growth, expand its presence in Europe, and advance the company’s next phase of international partnerships and product launches.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250112229499/en/
As CTO, Cameron will initially focus on the strategic expansion of Avanzanite’s footprint into 26 European countries, driving revenue growth for the current portfolio while also preparing for key new partnerships expected to materialize in 2025.
With over 25 years of experience in pharmaceutical operations, Mr. Cameron brings unparalleled expertise in global product distribution, regulatory compliance, and manufacturing of orphan medicines. His career spans leadership roles at some of the industry’s most innovative biopharmaceutical companies, including Genzyme (Sanofi), Synageva, and Amicus Therapeutics, where he was instrumental in launching more than 17 rare disease treatments.
Prior to joining Avanzanite, Cameron was Chief Operations Officer of Orphan Drug Consulting. Most recently in a corporate role, Mr. Cameron served as Senior Vice President of Technical Operations at Amicus Therapeutics, overseeing global product supply for small molecules, biologics, and gene therapies. Earlier in his career, he played a pivotal role at Genzyme, where he helped establish and scale supply chain operations across Europe and led global commercial supply efforts.
“We are thrilled to welcome Jason to our leadership team, which we proudly refer to as “Avanzanite’s Champions League,” said Adam Plich, Founder and CEO of Avanzanite. “Jason’s deep experience in global pharmaceutical operations, especially in rare disease markets, will be invaluable as we continue to expand our reach and deliver life-changing treatments to patients across Europe and beyond.” Plich continued, "Our long-term vision is to ensure that no patient is left behind when facing a rare disease, and Jason’s expertise and shared commitment to this mission will be instrumental in our success."
In his role, Cameron will oversee key operational functions, including supply chain management, manufacturing, quality assurance, regulatory compliance, and launch management. His leadership will ensure that Avanzanite can continue to provide timely, compliant, and high-quality product supply to patients across multiple regions while laying the groundwork for continued expansion into new markets.
"It’s an exciting opportunity to join Avanzanite and help realize its vision of improving access to orphan medicines for underserved patient populations," said Jason Cameron. "I look forward to working closely with the talented Avanzanite team to strengthen our operational capabilities and further our mission to make a lasting difference in the lives of rare disease patients." Cameron will be based in London, UK.
In 2024, Avanzanite continued its expansion in the European orphan drug market, reaching over 120 patients across 12 markets and generating revenue in six countries. With two authorized medicinal products in its portfolio, the Company is now poised to extend its presence to 26 European countries following the recent authorization of an orphan medicine for acanthamoeba keratitis.
About Avanzanite Bioscience
At Avanzanite Bioscience, we believe the world is full of untapped potential. Our mission is to unlock this potential, bringing life-changing treatments to underserved patient populations and overlooked markets. We are committed to ensuring that no patient is left behind when facing a debilitating rare disease. By acquiring, licensing, and distributing approved or late-stage medicines for rare diseases, we navigate European commercialization hurdles, ensuring that valuable medicines reach the markets and patient populations that need them most.
Founded in 2022 and headquartered in Amsterdam, the Netherlands, Avanzanite operates across Europe, with a growing infrastructure dedicated to serving patients and partners alike.
For more information, visit www.avanzanite.com.
Jason Cameron, Chief Technical Officer, Avanzanite Bioscience (Photo: Business Wire)
PHILADELPHIA (AP) — The Eagles need a new offensive coordinator.
Ask most fans, commentators — and, privately, some players — and the change from Kevin Patullo was inevitable long before Philadelphia actually made the move this week in the wake of a playoff loss.
There's a “help wanted” sign for the new boss of an offense — one loaded with elite talent such as Jalen Hurts, Saquon Barkley, A.J. Brown and DeVonta Smith — that fell way short as the Eagles failed in their bid to win consecutive Super Bowl titles.
Coach Nick Sirianni and general manager Howie Roseman were vague on details Thursday about why they waited until the end of the season to make the move — the Eagles ranked 24th in yards per game (311) and 19th in points per game (19.3) — and less clear on what they wanted out of a new coordinator.
“You’re looking to continue to evolve as an offense, and I’m looking to bring in the guy that’s going to best help us do that,” Sirianni said. “I think that there are many different ways to be successful on offense and everybody has different styles, everybody has different players, and there’s many different ways to be successful.”
The Eagles have plenty of credible candidates to choose from — everyone from Josh McCown and Cam Turner to former NFL coaches Brian Daboll, Mike McDaniel and Kliff Kingsbury. The new OC could have complete autonomy to run the offense, though collaboration has been key under Sirianni.
No matter the coordinator, the Eagles expect to be contenders again after playing in two of the last four Super Bowls. Just winning an NFC East title doesn't cut it these days in Philly.
“If it doesn’t end with confetti falling on our heads, I don’t feel like it’s good enough,” Roseman said. “I know that we’re not going to win the Super Bowl every year. I think I know that from a broad perspective, but I believe we can. I go into every offseason thinking we’re going to do whatever it takes to win a Super Bowl.”
Two-time All-Pro offensive tackle Lane Johnson has built a Hall of Fame-level career and won two Super Bowls since the Eagles made him a 2013 first-round pick.
Retirement talk was a hot topic for most of the season.
Johnson turns 36 in May and did not play after Week 11 because of a foot injury. He did not talk to the media this week when the Eagles cleaned out their lockers.
Roseman kept private his conversation with Johnson about retirement. Johnson reworked his contract last May and is signed through 2027.
“You're talking about a Hall of Fame player who’s been a huge, huge part of any of our success that we’ve had, and when you watch him play, he’s still playing at an elite level,” Roseman said.
Brown is likely staying put.
While he isn't shy about airing his grievances, the wide receiver is often worth the distractions because of his production.
Just not this season.
Brown had 78 receptions (down from 106 in 2023) for 1,003 yards (he had 1,496 in 2022) and only five 100-yard games. Of course, some of that dip in production resulted from how he was used in Patullo's offense. The changes ahead are one reason why the Eagles are in no rush to give up on the 28-year star — along with the $43 million dead salary cap hit they'd take if Brown wasn't on the roster.
“It is hard to find great players in the NFL and A.J.’s a great player,” Roseman said. “I think from my perspective, that’s what we’re going out and looking for when we go out here in free agency and in the draft is trying to find great players who love football, and he’s that guy. I think that would be my answer.”
Special teams coach Michael Clay had a virtual interview Thursday for the same job with the Tampa Bay Buccaneers.
Sirianni also hasn't ruled out Patullo staying on the staff in a different role.
“I know Kevin’s going to have other opportunities, and obviously always want what’s best for Kevin and for his family, so we’ll see how that plays out,” Sirianni said.
Patullo could want a fresh start after his house was egged earlier this season and one area indoor golf establishment let fans hit golf balls into a photo of his face after the playoff loss.
AP NFL: https://apnews.com/hub/nfl
Philadelphia Eagles head coach Nick Sirianni speaks with the media during a news conference at the NFL football team's training facility, Thursday, Jan. 15, 2026, in Philadelphia. (AP Photo/Chris Szagola)
Philadelphia Eagles head coach Nick Sirianni speaks with the media during a news conference at the NFL football team's training facility, Thursday, Jan. 15, 2026, in Philadelphia. (AP Photo/Chris Szagola)
Philadelphia Eagles executive vice president and general manager Howie Roseman, left, looks over as head coach Nick Sirianni, right, speaks with the media during a news conference at the NFL football team's training facility, Thursday, Jan. 15, 2026, in Philadelphia. (AP Photo/Chris Szagola)
Philadelphia Eagles head coach Nick Sirianni, right, and executive vice president and general manager Howie Roseman, left, speaks with the media during a news conference at the NFL football team's training facility, Thursday, Jan. 15, 2026, in Philadelphia. (AP Photo/Chris Szagola)
Philadelphia Eagles head coach Nick Sirianni speaks with the media during a news conference at the NFL football team's training facility, Thursday, Jan. 15, 2026, in Philadelphia. (AP Photo/Chris Szagola)
